Gapping up
In reaction to earnings/guidance:
- THO +2.5%
Other news:
- ABOS +76.8% (in response with BIIB)
- BIIB +45.6% (reports Lecanemab confirmatory Phase 3 Clarity AD study met primary endpoint)
- NNOX +22.8% (submitted a 510(k) premarket notification to the FDA on Sept 26 for its multi-source 3D digital tomosynthesis system)
- OCGN +9.3% (entered into an exclusive license agreement with Washington University for the rights to develop manufacture and commercialize its proprietary intranasally delivered COVID-19 vaccine in the United States Europe and Japan)
- SNCR +7.9% (signs 3-yr extension with telecom operator Fastweb)
- LLY +7.4% (in response with BIIB)
- CWCO +6% (Hurricane Ian did not cause any damage)
- FYBR +5.5% (to join S&P Midcap 400)
- HAIN +4.2% (to move to S&P SmallCap 600 from S&P Midcap 400)
- GROY +3.1% (stock offering by selling shareholder)
Analyst comments:
- SHOO +1.8% (upgraded to Buy from Neutral at CL King)
- ILMN +1.7% (upgraded to Outperform from In-line at Evercore ISI)
- CCU +0.9% (upgraded to Neutral from Underweight at JP Morgan)